Inhibition of the Met Receptor in Mesothelioma
Open Access
- 15 November 2005
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (22) , 8122-8130
- https://doi.org/10.1158/1078-0432.ccr-05-1191
Abstract
Background: Expression of the Met receptor and its ligand, hepatocyte growth factor (HGF), has been observed in 74% to 100% and 40% to 85% of malignant pleural mesothelioma (MPM) specimens, respectively. HGF stimulation has been shown to enhance MPM cell proliferation, migration, cell scattering, and invasiveness.Keywords
This publication has 42 references indexed in Scilit:
- Therapeutic Targeting of Multiple Signaling Pathways in Malignant Pleural MesotheliomaOncology, 2005
- Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255Cancer Research, 2004
- The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variantsOncogene, 2004
- A novel germ line juxtamembrane Met mutation in human gastric cancerOncogene, 2000
- Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cellsOncogene, 2000
- Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomasOncogene, 2000
- Role of Focal Adhesion Proteins in Signal Transduction and OncogenesisCritical Reviews™ in Oncogenesis, 1997
- Characteristics of nine newly derived mesothelioma cell linesThe Annals of Thoracic Surgery, 1995
- Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene ProductScience, 1991
- Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell linesDifferentiation, 1988